253 related articles for article (PubMed ID: 33855606)
1. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy.
Lin YM; Taiji R; Calandri M; Odisio BC
Curr Oncol Rep; 2021 Apr; 23(6):67. PubMed ID: 33855606
[TBL] [Abstract][Full Text] [Related]
2. Interventional oncology for hepatocellular carcinoma.
Delicque J; Boulin M; Guiu B; Pelage JP; Escal L; Schembri V; Assenat E; Fohlen A
Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):530-537. PubMed ID: 27055387
[TBL] [Abstract][Full Text] [Related]
3. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
Petrowsky H; Sturm I; Graubitz O; Kooby DA; Staib-Sebler E; Gog C; Köhne CH; Hillebrand T; Daniel PT; Fong Y; Lorenz M
Eur J Surg Oncol; 2001 Feb; 27(1):80-7. PubMed ID: 11237496
[TBL] [Abstract][Full Text] [Related]
4. Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective.
Hafez N; Gettinger S
Cancer J; 2020; 26(2):144-148. PubMed ID: 32205539
[TBL] [Abstract][Full Text] [Related]
5. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
[TBL] [Abstract][Full Text] [Related]
6. Interventional oncology for liver and lung metastases from colorectal cancer: The current state of the art.
de Baere T; Tselikas L; Pearson E; Yevitch S; Boige V; Malka D; Ducreux M; Goere D; Elias D; Nguyen F; Deschamps F
Diagn Interv Imaging; 2015 Jun; 96(6):647-54. PubMed ID: 25985998
[TBL] [Abstract][Full Text] [Related]
7. Tailoring ablation strategies for colorectal liver metastases based upon rat sarcoma viral oncogene mutation status.
Calandri M; Odisio BC
Chin Clin Oncol; 2019 Oct; 8(5):51. PubMed ID: 31500432
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
9. Regional Therapies for Colorectal Liver Metastases: Systematic Review and Clinical Practice Guideline.
Karanicolas P; Beecroft JR; Cosby R; David E; Kalyvas M; Kennedy E; Sapisochin G; Wong R; Zbuk K;
Clin Colorectal Cancer; 2021 Mar; 20(1):20-28. PubMed ID: 33257278
[TBL] [Abstract][Full Text] [Related]
10. Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma.
Kamp WM; Sellers CM; Stein S; Lim JK; Kim HS
J Vasc Interv Radiol; 2020 Jun; 31(6):953-960. PubMed ID: 32376182
[TBL] [Abstract][Full Text] [Related]
11. Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation.
Mu L; Chapiro J; Stringam J; Geschwind JF
Cancer J; 2016; 22(6):365-372. PubMed ID: 27870678
[TBL] [Abstract][Full Text] [Related]
12. Thermal Ablation and Transarterial Chemoembolization are Characterized by Changing Dynamics of Circulating MicroRNAs.
Andrasina T; Juracek J; Zavadil J; Cechova B; Rohan T; Vesela P; Paldor M; Slaby O; Goldberg SN
J Vasc Interv Radiol; 2021 Mar; 32(3):403-411. PubMed ID: 33495063
[TBL] [Abstract][Full Text] [Related]
13. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
[TBL] [Abstract][Full Text] [Related]
14. Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer.
Cavallaro P; Bordeianou L; Stafford C; Clark J; Berger D; Cusack J; Kunitake H; Francone T; Ricciardi R
Clin Colorectal Cancer; 2020 Mar; 19(1):e8-e17. PubMed ID: 31899147
[TBL] [Abstract][Full Text] [Related]
15. The role of image-guided therapy in the management of colorectal cancer metastatic disease.
de Baere T; Tselikas L; Yevich S; Boige V; Deschamps F; Ducreux M; Goere D; Nguyen F; Malka D
Eur J Cancer; 2017 Apr; 75():231-242. PubMed ID: 28237869
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
[TBL] [Abstract][Full Text] [Related]
17. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
[TBL] [Abstract][Full Text] [Related]
18. New applications of ultrasonography: interventional ultrasound.
Solbiati L
Eur J Radiol; 1998 May; 27 Suppl 2():S200-6. PubMed ID: 9652523
[TBL] [Abstract][Full Text] [Related]
19. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
20. What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update.
Arellano RS
Curr Oncol Rep; 2020 Jul; 22(10):105. PubMed ID: 32725433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
